McGrath Second Quarter Earnings and Conference Call Scheduled for July 24, 2025
McGrath RentCorp will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on July 24, 2025, to discuss the results. The conference call may be accessed by dialing 1-800-245-3047 (international callers dial 1-203-518-9765), or by listening to the simultaneous webcast on https://investors.mgrc.com/. A replay will be available for 7 days following the call by dialing 1-800-839-5630 (international callers dial 1-402-220-2557). In addition, a live audio webcast and replay of the call may be found in the investor relations section of the Company's website at https://investors.mgrc.com/events-and-presentations.
ABOUT MCGRATH:
McGrath RentCorp (Nasdaq: MGRC) is a leading business-to-business rental company in North America with a strong record of profitable business growth. Founded in 1979, McGrath's operations are centered on modular solutions through its Mobile Modular and Mobile Modular Portable Storage businesses. In addition, its TRS-RenTelco business offers electronic test equipment rental solutions. The Company's rental product offerings and services are part of the circular supply economy, helping customers work more efficiently, and sustainably manage their environmental footprint. With over 40 years of experience, McGrath's success is driven by a focus on exceptional customer experiences. This focus has underpinned the Company's long-term financial success and supported over 30 consecutive years of annual dividend increases to shareholders, a rare distinction among publicly listed companies.
McGrath is headquartered in Livermore, California. Additional information about McGrath and its businesses is available at mgrc.com and investors.mgrc.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
What To Expect From Lindblad Expeditions's (LIND) Q2 Earnings
Cruise and exploration company Lindblad Expeditions (NASDAQ:LIND) will be reporting results this Monday before market open. Here's what you need to know. Lindblad Expeditions beat analysts' revenue expectations by 18.8% last quarter, reporting revenues of $179.7 million, up 17% year on year. It was an exceptional quarter for the company, with an impressive beat of analysts' EPS estimates and a solid beat of analysts' EBITDA estimates. Is Lindblad Expeditions a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Lindblad Expeditions's revenue to grow 16.5% year on year to $159 million, improving from the 9.4% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.29 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lindblad Expeditions has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 5.8% on average. Looking at Lindblad Expeditions's peers in the travel and vacation providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Carnival delivered year-on-year revenue growth of 9.5%, beating analysts' expectations by 1.7%, and Delta reported flat revenue, topping estimates by 1.5%. Carnival traded up 5.9% following the results while Delta was also up 11.9%. Read our full analysis of Carnival's results here and Delta's results here. Investors in the travel and vacation providers segment have had steady hands going into earnings, with share prices flat over the last month. Lindblad Expeditions is down 7.4% during the same time and is heading into earnings with an average analyst price target of $15 (compared to the current share price of $11.73). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
36 minutes ago
- Yahoo
PlayStudios (MYPS) To Report Earnings Tomorrow: Here Is What To Expect
Digital casino game platform PlayStudios (NASDAQ:MYPS) will be announcing earnings results this Monday after market hours. Here's what you need to know. PlayStudios missed analysts' revenue expectations by 1.4% last quarter, reporting revenues of $62.71 million, down 19.4% year on year. It was a satisfactory quarter for the company, with a solid beat of analysts' adjusted operating income estimates but a miss of analysts' daily active users estimates. It reported 2.63 million monthly active users, down 24.7% year on year. Is PlayStudios a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting PlayStudios's revenue to decline 15.9% year on year to $61.07 million, a further deceleration from the 6.7% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.03 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. PlayStudios has missed Wall Street's revenue estimates five times over the last two years. Looking at PlayStudios's peers in the consumer discretionary segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Rush Street Interactive delivered year-on-year revenue growth of 22.2%, beating analysts' expectations by 7.6%, and Churchill Downs reported revenues up 4.9%, topping estimates by 1.4%. Rush Street Interactive traded up 25.7% following the results while Churchill Downs was also up 4.1%. Read our full analysis of Rush Street Interactive's results here and Churchill Downs's results here. Investors in the consumer discretionary segment have had steady hands going into earnings, with share prices flat over the last month. PlayStudios is down 10.7% during the same time and is heading into earnings with an average analyst price target of $2.88 (compared to the current share price of $1.09). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
36 minutes ago
- Yahoo
What To Expect From Vertex Pharmaceuticals's (VRTX) Q2 Earnings
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here's what to look for. Vertex Pharmaceuticals missed analysts' revenue expectations by 2.3% last quarter, reporting revenues of $2.77 billion, up 3% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' EPS estimates and full-year revenue guidance slightly missing analysts' expectations. Is Vertex Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Vertex Pharmaceuticals's revenue to grow 9.8% year on year to $2.90 billion, improving from the 6.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.25 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Vertex Pharmaceuticals has missed Wall Street's revenue estimates three times over the last two years. Looking at Vertex Pharmaceuticals's peers in the therapeutics segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 7.3%, beating analysts' expectations by 13.7%, and Moderna reported a revenue decline of 41.1%, topping estimates by 10.7%. Biogen traded up 3.9% following the results. Read our full analysis of Biogen's results here and Moderna's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Vertex Pharmaceuticals's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $505.19 (compared to the current share price of $464). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
